TG Therapeutics | TGTX - Operating Expenses


TG Therapeutics reported $174.04M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Alaunos Therapeutics USD 952K 60K Jun/2026
Amgen USD 5.69B 6B Sep/2026
Ardelyx USD 133.3M 6.04M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Bayer EUR 9.92B 121M Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
Corcept Therapeutics USD 225.75M 10.9M Sep/2026
Curis USD 11.52M 2.5M Mar/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
TG Therapeutics USD 174.04M 44.62M Sep/2026
Verastem USD 63.57M 4.56M Mar/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026